These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 28168639)

  • 1. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
    Stoneman P; Gilligan P; Mahon P; Sheahan R
    Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
    Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
    Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.
    Simon A; Niederdoeckl J; Skyllouriotis E; Schuetz N; Herkner H; Weiser C; Laggner AN; Domanovits H; Spiel AO
    Europace; 2017 Feb; 19(2):233-240. PubMed ID: 28175295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I; Graydon R; Camm AJ
    Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
    Pohjantähti-Maaroos H; Hyppölä H; Lekkala M; Sinisalo E; Heikkola A; Hartikainen J
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):114-120. PubMed ID: 28849946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
    Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
    Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
    Guerra F; Matassini MV; Scappini L; Urbinati A; Capucci A
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1067-75. PubMed ID: 25096598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.
    Buccelletti F; Iacomini P; Botta G; Marsiliani D; Carroccia A; Gentiloni Silveri N; Franceschi F
    J Clin Pharmacol; 2012 Dec; 52(12):1872-8. PubMed ID: 22167572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M
    Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D
    Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vernakalant in hospital emergency practice: safety and effectiveness].
    Carbajosa Dalmau J; Cosín-Sales J; Pérez-Durá MJ; Noceda J; Urtubia-Palacios A; Hernández-Sori N; Peiró-Gómez A; Jacob J; Llorens P; Ruescas-Gómez L; Martín-Martínez A
    Emergencias; 2017 Dic; 29(6):397-402. PubMed ID: 29188914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis.
    McIntyre WF; Healey JS; Bhatnagar AK; Wang P; Gordon JA; Baranchuk A; Deif B; Whitlock RP; Belley-Côté ÉP
    Europace; 2019 Aug; 21(8):1159-1166. PubMed ID: 31292622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.